Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver.

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

In this video, I will review some of the stock purchases made by members of the U.S. Congress. Politicians such as Nancy Pelosi and Marjorie Taylor Greene, among others, have acquired significant ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to US$1.3 billion to boost its pipeline beyond its blockbuster weight-loss and diabetes drugs.

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Shares of Verve Therapeutics, Inc. (VERV) rocketed 75% in pre-market on Tuesday after Eli Lilly and Company (LLY) announced ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

OnePlus is bringing a couple of interesting products to the United States and Canada this summer, including its flagship Buds ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.